NAFLD affects about 30% of people in Western countries and 10% of people in Asia. In the United States rates are around 35% with about 7% having the severe form NASH. NAFLD affects about 10% of children in the United States. Recently the term Metabolic dysfunction-associated<unk>  (MAFLD) has been proposed to replace NAFLD. MAFLD is a more inclusionary diagnostic name as it is based on the detection of fatty<unk>  by histology (biopsy),medical imaging or blood biomarkers but should be accompanied by either overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation. The new definition no longer excludes alcohol consumption or coexistence of other<unk><unk> s such as viral hepatitis. Using this more inclusive definition, the global prevalence of MAFLD is an astonishingly high 50.7%. Indeed, also using the old NAFLD definition, the<unk>  is observed in up to 80% of obese people, 35% of whom progress to NASH, and in up to 20% of normal weight people, despite no evidence of excessive alcohol consumption.<unk>  is the most common cause of abnormal<unk>  function tests in the United States. Fatty<unk>  is more prevalent in Hispanic people than white, with black people having the lowest susceptibility. In the study of Children of the 90s, 2.5% born in 1991 and 1992 were found by ultrasound at the age of 18 to have non-alcoholic<unk> ; five years later transient elastography (fibroscan) found over 20% to have the fatty deposits on the<unk> , indicating non-alcoholic<unk> ; half of those were classified as severe. The scans also found that 2.4% had the<unk>  scarring, which can lead to cirrhosis.
Fatty liver disease
Wilson's disease
Alcoholic liver disease
Viral hepatitis
Alcoholic hepatitis
Primary sclerosing cholangitis
Non-alcoholic fatty liver disease
Autoimmune hepatitis